In reply [12]

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 2113-2114

  Figg, William D ^a   Retter, Avi ^a   Steinberg, Seth M ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; FOLLOW UP; HUMAN; LETTER; MONOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER;

EID: 33846803793     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.296     Document Type: Letter

References (1)

1. Dahut WL, Gulley JL, Arlen PM, et al: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22:2532-2539, 2004